



Matti Heinonen (Arvela) appointed as CEO of Gentian Diagnostics

Moss, 22 July 2024

Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic tests, is pleased to announce that Matti Heinonen* is appointed to the position of CEO. Matti brings extensive experience from leading positions in the global healthcare industry, with focus on the diagnostics and pharma segments.

Throughout his career, Matti has delivered exceptional achievements for global companies, like Amgen, with focus on driving profitable growth. During the last 3 years, Matti has acted as VP Immunodiagnostics and most recently as CCO for Medix Biochemica. Medix is a well-established raw material supplier for the international diagnostics industry. Matti is a citizen of Finland, and he has previous international experience from the US and Europe. Matti will take on the role no later than February 2025.

“Gentian’s mission to protect lives and reduce costs by enabling better treatment decisions with significantly greater operational efficiency is truly inspiring. The company boasts a strong team with a proven track record, having achieved impressive results. Gentian’s ambition to become a leading diagnostic partner, serving millions of patients, is both exciting and credible.” says Matti Heinonen, incoming CEO of Gentian Diagnostics.

“We are looking forward to working with Matti and together steering Gentian Diagnostics to the next level of growth. We are convinced that Matti’s background as Master of Biochemistry combined with business acumen coming from international leadership positions in our industry will secure our ambition of continuous double-digit profitable sales growth.” says Hilja Ibert, chairperson of the board.

* Please note that Matti has recently reassumed his birth name Heinonen. Before he has worked for several years under the last name Arvela.

For further information please contact:
Hilja Ibert, Chairperson of the Board
hilja.ibert@gentian.no
+47 919 05 242 (mobile)



About Gentian Diagnostics

Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in vitro diagnostic reagents. Gentian's expertise and focus lies within homogenous immunoassays, specifically infections, inflammations, kidney failures and congestive heart failures. By converting existing and clinically relevant biomarkers to the most efficient automated, high-throughput analysers, the company contributes to saving costs and protecting life. Gentian is headquartered in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA, and China. For more information, please visit www.gentian.com.

This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.